Ontario Invests Additional $4.6 Million in McMaster Nuclear Reactor to Expand Medical Isotope Production Capacity

The Government of Ontario, Canada, recently announced an additional investment of $4.6 million in the McMaster Nuclear Reactor to expand the production capacity of life-saving medical isotopes, supporting more cancer patients in accessing the critical radioisotopes needed for diagnosis and treatment.

From left to right: Josip Zikic, Chief Nuclear Officer at McMaster University; Nolan Quinn, Minister of Colleges and Universities, Research Excellence and Security; Stephen Lecce, Minister of Energy and Mining; Susan Tighe, President and Vice-Chancellor of McMaster University; and Victor Fedeli, Minister of Economic Development, Job Creation and Trade. (Georgia Kirkos/McMaster University)

This investment builds on a previous $18 million in funding, with the goal of enabling the McMaster Nuclear Reactor to operate 24 hours a day, 7 days a week, thereby increasing neutron production and boosting the supply of custom medical isotopes used in new drug development and targeted therapy research. According to published information, these investments will increase the reactor's research capacity by 300% and enable the production of isotopes sufficient for up to 84,000 cancer treatments annually.

McMaster University stated that as a key institution for nuclear research in Canada, it will leverage this investment to enhance the production capacity of critical medical isotopes, support groundbreaking research, and provide practical training for students, ultimately serving the treatment needs of patients in Ontario and around the world.

The total investment by the Government of Ontario in the McMaster Nuclear Reactor has now reached $26.9 million. Officials noted that the growing demand for medical isotopes in cancer treatment necessitates enhancing the reactor's operational capacity, which will help expand local treatment resources and solidify Ontario's advantage in nuclear medicine and medical isotope supply.

Radioisotopes play a vital role in cancer diagnosis and treatment. McMaster University currently supplies approximately 60% of the global demand for Iodine-125, a medical isotope used to treat various cancers. At present, the McMaster Nuclear Reactor supports the treatment of over 70,000 cancer patients annually.

Ontario plans to double its medical isotope production by 2030. With the extended operating hours of the McMaster Nuclear Reactor, the facility is also expected to create more jobs and research opportunities, driving the development of targeted therapy technologies for both the Canadian and global markets.